Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HRS-7535 in Chinese Obese Subjects
NCT06250946Phase 2Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HRS-7535 in obesity (5 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoint: Percent change in body weight from baseline at Week 26. Started Feb 2024; status: completed.
02
Drugs
HRS-7535
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06250946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06250946.